Perlegen entered into 3 research agreements. With Pfizer, Perlegen will identify genetic contributors of cardiovascular disease. For Bristol-Myers Squibb, Perlegen will identify markers for patient response to medications in BMS’ portfolio and will scan genomes of clinical trial patients. Perlegen entered into a similar deal with GlaxoSmithKline.